Surgery precedes biologics but comes after saline irrigations and topical intranasal corticosteroids in a new treatment algorithm for US clinicians treating patients who have chronic rhinosinusitis ...
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life ...
This study investigated combination treatment of antibiotics plus corticosteroids among persons with aspirin-exacerbated respiratory disease, a subtype of chronic rhinosinusitis with nasal polyposis ...
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 ...
Please provide your email address to receive an email when new articles are posted on . Extended use of omalizumab up to 1 year showed efficacy for the treatment of uncontrolled chronic rhinosinusitis ...
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Please provide your email address to receive an email when new articles are posted on . Treatment also reduced oral corticosteroid (OCS) doses among patients with severe asthma who depended on OCS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback